Aldeyra The Asset Resilience Ratio
Aldeyra The asset resilience ratio. Aldeyra The (ALDX) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aldeyra The defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aldeyra The (2014–2025)
Asset resilience ratio of Aldeyra The from 2014 to 2025. This chart shows how Aldeyra The's Asset Resilience Ratio has changed over time. Read ALDX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aldeyra The's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Aldeyra The balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Aldeyra The maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Aldeyra The Industry Peers by Asset Resilience Ratio
Compare Aldeyra The's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Aldeyra The Asset Resilience Ratio by Year (2014–2025)
Aldeyra The asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Aldeyra The.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $72.06 Million | -- |
| 2024-12-31 | 44.57% | $46.62 Million | $104.61 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $148.33 Million | -- |
| 2022-12-31 | 16.48% | $29.88 Million | $181.29 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $233.14 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $83.35 Million | -- |
| 2019-12-31 | 38.32% | $28.94 Million | $75.52 Million | -10.31pp |
| 2018-12-31 | 48.63% | $46.24 Million | $95.09 Million | -3.26pp |
| 2017-12-31 | 51.89% | $22.92 Million | $44.17 Million | +0.69pp |
| 2016-12-31 | 51.21% | $12.90 Million | $25.19 Million | +5.32pp |
| 2015-12-31 | 45.89% | $12.94 Million | $28.20 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $8.79 Million | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary… Read more